Bayer Aktiengesellschaft

Bayer Intellectual Property Gmbh

Bayer Animal Health Gmbh

Elanco Animal Health Gmbh

Seattle Genetics, Inc.

Bayer Pharma Aktiengesellschaft

Charité – Universitätsmedizin Berlin

Freie Universitat Berlin

Iring Heisler

Hans-Georg Schwarz

Andreas Turberg

Kerstin Ilg

Werner Hallenbach

Yolanda Cancho Grande

Alexander Arlt

Ulrich Ebbinghaus-Kintscher

Martin Fuesslein

Peter Jeschke

Nils Griebenow

Heinz-Juergen Wroblowsky

Bernd Alig

Ulrich Görgens

Sergii Pazenok

Ulrich Goergens

Marc Linka

Arunas Jonas Damijonaitis

Joachim Schuhmacher

Joachim Telser

Wei Zhuang

Daniel Kulke

Charlotte Christine Kopitz

Thomas Simon Ilg

Antje Kahnert

Walter Hübsch

Adeline Köhler

Kirsten Börngen

Claudia Böhm

Estella Buscato Arsequell

Walter Huebsch

Kerstin Unterschemmann

Ulf Bömer

Hans-Georg Lerchen

Peter Lösel

Sascha Eilmus

Niels Lindner

Karl-Heinz Thierauch

Beatrix Stelte-Ludwig

Johannes Köbberling

Simone Greven

Christoph Mahlert

Peter Loesel

Sherif El Sheikh

Maike Hink

Claudia Welz

Adeline Koehler

Sven Golfier

Lars Linden

Yolanda Cancho-Grande

Jörg Willuda

Axel Harrenga

Martin Füsslein

Joachim Schumacher

Martin Füßlein

Kirsten Boerngen

Sandra Bruder

Hannah Jöriβen

Kerstin Berhörster

Maria De Lourdes Mottier

Gerald Beddies

Hendrik Fuchs

Claudia Boehm

Ingo Limberg

Isa Jana Irina Janssen

Weijie Ha

Rudolf Beier

Heike Petrul

Sandra Borkowski

Jörg Cramer

Oleksandr Mandzhulo

Philipp Winter

Steffen Müller

Kerstin Berhoerster

Robin Maximilian BÄR

Arunas Damijonaitis Jonas

Wijie Ha

Ha Weijie

Ulrich Ebbinhaus-Kintscher

Matthias Melzig

Philip Hebestreit

Mark Sutherland

Christopher Bachran

The present invention relates to novel compounds of general formula (I): withA being A1 or A: andin which T, X, Y, Ro, R, Rand Rare as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for the treatment, control and/or prevention of diseases, in particular of helminth infections, as a sole agent or in combination with other active ingredients.

Anthelmintic compounds

The present invention covers new isoquinoline compounds of general formula (I): in which A, R, R, R, R, R, R, and Q are as defined herein, methods of preparing the compounds, intermediate compounds useful for preparing the compounds of formula (I), pharmaceutical compositions and combinations comprising the compounds of formula (I) and the use of the compounds of formula (D) for manufacturing pharmaceutical compositions for the treatment, control and/or prevention of diseases, in particular of helminth infections, as a sole agent or in combination with other active ingredients.

Isoquinoline derivatives and their use for the treatment of parasitic infections

The present invention relates to novel heteroaryl-substituted aminoalkyl azole compounds of the general formula (I), in which the structural elements Y, Q, Q, R, R, Rand Rhave the meaning given in the description, to formulations and compositions comprising such compounds and for their use in the control of animal pests including arthropods and insects in plant protection and to their use for control of ectoparasites on animals.

Heteroaryl-substituted aminoalkyl azole compounds as pesticides

The present invention relates to novel heteroaryl-triazole and heteroaryl-tetrazole compounds of the general formula (I), in which the structural elements Y, Q, Q, R, R, R, R, Rand Rhave the meaning given in the description, to formulations and compositions comprising such compounds and for their use in the control of animal pests including arthropods and insects in plant protection and to their use for control of ectoparasites on animals.

Heteroaryl-triazole and heteroaryl-tetrazole compounds as pesticides

The present invention relates to novel heteroaryl-triazole and heteroaryl-tetrazole compounds of the general formula (I), in which the structural elements Y, Q, Q, R, R, R, Rand Rhave the meaning given in the description, to formulations and compositions comprising such compounds and for their use in the control of animal pests including arthropods and insects in plant protection and to their use for control of ectoparasites on animals.

The present invention covers new quinoline compounds of general formula (I), in which A, R, R, R, R, R, R, and Q are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment, control and/or prevention of diseases, in particular of helminth infections, as a sole agent or in combination with other active ingredients. 

Quinoline derivatives

The present invention relates to novel heteroaryl-triazole and heteroaryl-tetrazole compounds of the general formula (I), in which the structural elements Y, Q, Q, R, R, R, Rand Rhave the meaning given in the description, to formulations and compositions comprising such compounds and for their use in the control of animal pests including arthropods and insects in plant protection and to their use for control of ectoparasites on animals. 

The present invention covers azaquinoline compounds of general formula (I), with A being (A1) or (A2), and in which T, R, R, R, R, R, Rand Q are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment, control and/or prevention of diseases, in particular of helminth infections, as a sole agent or in combination with other active ingredients. 

Azaquinoline derivatives

The present application relates to the use of fused heteroaromatic pyrrolidones for treatment and/or prophylaxis of allergic and/or inflammatory diseases in animals and to the use thereof for production of medicaments for treatment and/or prophylaxis of allergic and/or inflammatory diseases in animals, especially of atopic dermatitis and/or Flea Allergy Dermatitis, and especially in domestic animals, particularly in dogs.

Use of fused heteroaromatic pyrrolidones for treatment and prevention of diseases in animals

The present invention provides immunoconjugates composed of antibodies, e.g., monoclonal antibodies, or antibody fragments that bind to mesothelin, that are conjugated to cytotoxic agents, e.g., maytansine, or derivatives thereof, and/or co-administered or formulated with one or more additional anti-cancer agents. The immunoconjugates of the invention can be used in the methods of the invention to treat and/or diagnose and/or monitor cancers, e.g. solid tumors, recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for the membrane-anchored, 40 kDa mesothelin polypeptide, which is overexpressed in several tumors, such as pancreatic and ovarian tumors, mesothelioma and lung cancer cells.

Anti-mesothelin immunoconjugates and uses therefor

The present invention provides immunoconjugates composed of antibodies, e.g., monoclonal antibodies, or antibody fragments that bind to mesothelin, that are conjugated to cytotoxic agents, e.g., maytansine, or derivatives thereof, and/or co-administered or formulated with one or more additional anti-cancer agents. The immunoconjugates of the invention can be used in the methods of the invention to treat and/or diagnose and/or monitor cancers, solid tumors, recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for the membrane-anchored, 40 kDa mesothelin polypeptide, which which is overexpressed in several tumors, such as pancreatic and ovarian tumors, mesothelioma and lung cancer cells.

The present invention provides immunoconjugates composed of antibodies, e.g., monoclonal antibodies, or antibody fragments that bind to mesothelin, that are conjugated to cytotoxic agents, e.g., maytansine, or derivatives thereof, and/or co-administered or formulated with one or more additional anti-cancer agents. The immunoconjugates of the invention can be used in the methods of the invention to treat and/or diagnose and/or monitor cancers, e.g. solid tumors. The immunoconjugates comprise antibodies and functional fragments containing such antigen-binding regions that are specific for the membrane-anchored, 40 kDa mesothelin polypeptide, which is overexpressed in several tumors, such as pancreatic and ovarian tumors, mesothelioma and lung cancer cells.

The present application relates to new binder-drug conjugates (ADCs) of N,N-dialkylauristatins that are directed against the target C4.4a, to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for treating and/or preventing illnesses, and also to the use of these ADCs for producing medicaments for treating and/or preventing illnesses, more particularly hyperproliferative and/or angiogenic diseases such as, for example, cancer diseases. Such treatments may be practiced as a monotherapy or else in combination with other medicaments or further therapeutic measures.

Binder-drug conjugates (ADCs) and use thereof

Growing community of inventors

Düsseldorf, Germany

Iring Heisler